공시 • Oct 18
Cognetivity Neurosciences Ltd. announced that it has received CAD 0.01 million in funding On October 17, 2023, Apogee 21 Holdings, Inc. closed the transaction. The transaction included participation from a single investor 공시 • Jul 08
Cognetivity Neurosciences Ltd. Announces Eisai's Leqembi Approval for the Treatment of Alzheimer's Disease Cognetivity Neurosciences Ltd. announced that Eisai's Leqembi has achieved full FDA approval for the treatment of Alzheimer's disease, news that brings hope to tens of millions of sufferers and at-risk individuals worldwide. Leqembi received accelerated FDA approval in January 2023 due to its ability to clear amyloid plaques - harmful clumps of protein in the brain associated with Alzheimer's disease. Previously, the U.S. government's Medicare health plan for people aged 65 and over had restricted coverage only to patients in a clinical trial. Standard approval, the first of its kind for Alzheimer's disease, means that Leqembi will now be covered for all patients, although the Centers for Medicare and Medicaid Services (CMS) is linking reimbursement to patient participation in a health agency database, known as a registry. Since Alzheimer's is a disease of aging, most U.S. patients are insured by Medicare. CognICA is being used successfully to screen populations of individuals at risk of mild cognitive impairment, and reliably identifies those who show early signs of cognitive problems and require further assessment. Following clinical diagnosis, the technology platform is used to monitor changes in cognitive function among patients receiving monthly treatment, demonstrating the ability to deliver the CMS mandated reporting on patient progress. The speed, precision and ability to scale of CognICA give it a unique position in the market for the large-scale detection and monitoring of individuals with early stage Alzheimer's disease and other brain health issues. Cognetivity Neurosciences remains dedicated to utilizing its AI platform technology to transform the landscape of brain health globally, enhance the quality of care provided to patients and to reduce the burden and cost to providers and payers, delivering the company's vision of A Brighter Mind for a Fuller Life. 공시 • Feb 16
Cognetivity Neurosciences Ltd. Announces Release an Update Version of Its Tool, CognICATM Cognetivity Neurosciences Ltd. announced that it has released an updated version of its tool, CognICATM. CognICA is a unique platform for the assessment and monitoring of brain health: powered by artificial intelligence (AI), FDA-registered and CE-marked, and commercially deployed in North America, East and Southeast Asia, the Middle East, and the UK's National Health Service (NHS). The company's technology uses AI and machine learning (ML) techniques to help detect the earliest signs of cognitive impairment by providing a fast, sensitive and objective measure of brain function. This enables CognICATM to facilitate the early identification of individuals with brain health issues, at a time when interventions are most effective, as well as supporting their long-term treatment management and monitoring. Crucially, as a fundamentally AI and ML-based tool, CognICA can be continually expanded and enhanced over time, trained on more data from an increasing number of global deployments to build increasingly refined, disease-specific models. In the case of Alzheimer's disease, for example, the company already holds a patent covering the use of an AI-based system to estimate levels of core biomarkers of neurodegeneration in the brain, such as amyloid (A) protein. The tool is tablet-based, self-administered and independent of language and education biases, thereby making it highly effective for comprehensive, scaled screening programs in all geographies. Among a range of improvements, the latest version of CognICA includes local data storage functionality, facilitating deployment in an expanded range of territories and thus enlarging the potential market for the technology. It also permits unlimited scaling, ensuring that users benefit from a rapid, efficient experience regardless of user load. 공시 • Jan 25
Cognetivity Neurosciences Ltd.'s CognICA Platform Successfully Monitors Cognitive Performance in Alzheimer's Patients Receiving Disease- Modifying Therapy Cognetivity Neurosciences Ltd. announced that its CognICA tool has demonstrated effectiveness in tracking cognitive function during the treatment of Alzheimer's disease patients with the disease-modifying therapy Aduhelm (aducanumab), manufactured by Biogen. CognICA was used in clinical practice at Mediclinic Parkview Hospital in Dubai, UAE, to screen 108 patients coming into the neurology clinic for cognitive impairment. The tool was then used to monitor the cognition of the patients who received a diagnosis of Alzheimer's disease and were eligible for treatment with Aduhelm, a US Food and Drug Administration (FDA)-approved drug that directly targets amyloid beta pathology. The results showed that patients who received Aduhelm did not show cognitive decline, with two patients showing a significant improvement in cognitive performance. They demonstrate the use of CognICA as a sensitive screening and monitoring tool to support detection of cognitive impairment and measure changes in cognitive performance in response to disease-modifying therapies for Alzheimer's. As such, the tool is perfectly suited to support the dawning era of targeted therapies forneurodegenerative disease as evidenced by the FDA's approval, in the first week of 2023, of a second drug directly targeting amyloid beta pathology, LeqembiTM (lecanemab). Early detection and diagnosis will be critical to the rapid, large-scale rollout of this family of therapeutics since they havebeen approved for early-stage disease, in the form of mild cognitive impairment (MCI) or mild dementia due to Alzheimer's. Outstanding sensitivity to early-stage disease the ability to identify changes in the brain is CognICA's greatest strength, as demonstrated in thousands of patients and numerous peer-reviewed publications. 